| Name | Title | Contact Details |
|---|
InReachs mission is to be a leader in providing innovative housing, employment and community services to support people with intellectual, developmental and other disabilities and their families. This year, InReach will serve over 1,200 people – helping these individuals develop important life skills such as managing money, shopping for groceries, accessing transportation and community resources, and finding and maintaining employment. We also help people engage in the activities that they enjoy, such as participating in church communities, volunteering for service projects, planning vacations and attending fitness, art and music classes. Join our team! InReach excels at hiring qualified individuals with integrity and compassion. We develop our staff to ensure success in each position, equipping them with the information and skills they need to provide quality services to individuals with intellectual and developmental disabilities. We strive to be an employer of choice, offering a variety of positions for both Employees and Independent Contractors. All candidates must possess a sincere desire to support individuals with developmental disabilities. Please download and complete the Application Form below when applying for one or more positions. You may then save the fillable form and submit your applications electronically to jobs@inreachnc.org, in person, or by mail to : InReach Attn: Human Resources 4530 Park Rd. Suite 300 Charlotte NC 28209 Application: http://inreachnc.org/images/pdfs/inreachapplicationrev2.21.pdf
C3 Workforce is a Southgate, MI-based company in the Business Services sector.
Shattuck Advertising is a Owosso, MI-based company in the Business Services sector.
Bind-Rite Services is a South Hackensack, NJ-based company in the Business Services sector.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.